LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a second Phase 1 clinical study of its novel heat shock protein 90 (Hsp90) inhibitor, STA-9090, with a once-a-week dosing schedule. In November, Synta announced the start of a Phase I clinical study of STA-9090 with a twice-a-week dosing schedule. STA-9090 is a synthetic, small molecule Hsp90 inhibitor with a novel chemical structure that is unrelated to the Hsp90 inhibitor geldanamycin or its family of related compounds, such as 17-AAG.
